Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib

TAIPEI and SAN DIEGO, Aug. 13, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, Silmitasertib, has been included in…

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.prnewswire.com:443/news-releases/senhwa-signs-agreement-with-taiwans-cde-for-covid-19-program-guiding-development-of-silmitasertib-301355382.html